TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28640385
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) consolidation therapy
Study: 17302926
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene measures provided by dental hygienists once every 3 weeks (Group A)
Study: 17302926
Drug: Nursing staff
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing staff provided daily oral hygiene after hands-on instructions (Group B)
Study: 15145325
Drug: Twice-daily isophane
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily isophane insulin (Group 2)
Study: 15145325
Drug: Basal/bolus isophane/lispro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal/bolus isophane/lispro insulin (Group 3)
Study: 15145325
Drug: Continue tablets
Normalized name: morphine Extended Release Oral Tablet [MS Contin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue tablets (Group 1)
Study: 11163559
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (200 microg/kg) before aortic cross‐clamp
Study: 9833044
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for eradication of Helicobacter pylori for one week
Study: 28486329
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (300 mg·d)
Study: 24130355
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin analog injections
Study: 24130355
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion therapy
Study: 21354608
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups without PAA and STMP; no treatment applied.
Study: 19695194
Drug: Ambroxol (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (4.5 mg/kg in 10 mL normal saline by intravenous injection after skin incision)
Study: 15562083
Drug: Single-injection paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection paravertebral block (PVB) with bupivacaine 5 mg/mL (1.5 mg/kg)
Study: 30672234
Drug: Long-snake moxibustion
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-snake moxibustion therapy, applied on acupoints of the governor vessel (Dazhui to Yaoshu) and bilateral Jiaji, once a day for 7 days, 4 courses total.
Study: 30672234
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medication (salazosulfapyridine and NSAIDs), for 7 days, 4 courses total.
Study: 8804803
Drug: Methotrexate 50
Normalized name: methotrexate 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 50 mg/m2 intramuscularly followed by misoprostol 800 micrograms vaginally
Study: 6383735
Drug: 0.1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 percent halcinonide cream
Study: 30182359
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day sodium selenite (GI)
Study: 30182359
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C/day (GII)
Study: 30130351
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ulipristal acetate daily for 7 days
Study: 27456689
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behavioural therapy (CBT) program, consisting of four sessions including psychoeducation, physical activity, and relaxation.
Study: 20080842
Drug: Osteoporosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis treatment (risedronate, strontium ranelate, zoledronic acid, denosumab)
Study: 15361699
Drug: Leptospirosis ARF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptospirosis ARF patients (group 1, P(creat) >442 micromol/l)
Study: 15361699
Drug: Leptospirosis ARF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptospirosis ARF patients (group 2, P(creat) < or =442 micromol/l)
Study: 9565284
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (added weekly chlorhexidine rinse)
Study: 8140926
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium (0, 5, 20, and 40 mg) for 6 weeks
Study: 30200910
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin)
Study: 24594871
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU or 40.32 μg)
Study: 23075357
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant medication (Control group).
Study: 15619404
Drug: Low-dose paclitaxel-eluting
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose paclitaxel-eluting stents
Study: 15619404
Drug: High-dose paclitaxel-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paclitaxel-eluting stents
Study: 12688622
Drug: Stringent environmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stringent environmental control (allergen impermeable covers, hot washing of bedding weekly, HEPA vacuum cleaner, hard floor for nursery)
Study: 7581965
Drug: Oral GHRP-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GHRP-6 (300 micrograms/kg)
Study: 7581965
Drug: Intravenous GHRH
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GHRH (GHRH-29, 1 microgram/kg)
Study: 2101864
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluconazole per day orally
Study: 2101864
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg amphotericin B per day orally
Study: 31891860
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake (breath alcohol concentration of 0.08 g/dL)
Study: 25296344
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) of the quadriceps muscle, twice daily for 7±1 days
Study: 17300627
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) prophylaxis (500 mg phosphate weekly)
Study: 15199346
Drug: Full-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose tenecteplase plus enoxaparin
Study: 15199346
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase plus abciximab
Study: 15199346
Drug: Full-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose tenecteplase plus unfractionated heparin
Study: 15199346
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of enoxaparin versus heparin
Study: 15199346
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of abciximab versus heparin
Study: 11779753
Drug: L-bandage
Normalized name: New-Skin Liquid Bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-bandage
Study: 9521232
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg)
Study: 9521232
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (20 mg)
Study: 7666123
Drug: ampicillin/sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin/sulbactam (2 g ampicillin plus 1 g sulbactam intravenously every 6 h)
Study: 7666123
Drug: cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotaxime (2 g intravenously every 6 h)
Study: 2533973
Drug: ANF 102-126
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF 102-126 (WY 47987) bolus injections at 1, 2, and 3 micrograms/kg i.v.
Study: 160068
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (2 puffs of 0.02 mg each)
Study: 160068
Drug: Fenoterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2 puffs of 0.2 mg each)
Study: 160068
Drug: Isoprenaline (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (inhaled at the end of the experiment)
Study: 30496870
Drug: Both HA-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HA-L and HA-I vaccines
Study: 23589562
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (activated 1 month after device implantation)
Study: 23589562
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (activated 6 months after device implantation)
Study: 23589562
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (both groups)
Study: 16886724
Drug: risperidone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (2.5 +/- 1 mg/day)
Study: 6397578
Drug: Radiotherapy 3000
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy 3000 rad/10 fractions (treatment 1)
Study: 6397578
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus metronidazole 6 gm/m2 (treatment 2)
Study: 31405867
Drug: Omadacycline 100
Normalized name: omadacycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline 100 mg i.v.
Study: 31405867
Drug: Omadacycline 300
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 300 mg i.v.
Study: 25619634
Drug: Weekly drug
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly drug administration
Study: 25619634
Drug: Monthly drug
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly drug administration
Study: 19368768
Drug: Split H7N1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split H7N1 virus vaccine with 12 microg haemagglutinin
Study: 19368768
Drug: Split H7N1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split H7N1 virus vaccine with 24 microg haemagglutinin
Study: 19368768
Drug: Split H7N1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split H7N1 virus vaccine with 12 microg haemagglutinin and 300 microg aluminium hydroxide adjuvant
Study: 19368768
Drug: Split H7N1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split H7N1 virus vaccine with 24 microg haemagglutinin and 600 microg aluminium hydroxide adjuvant
Study: 16448520
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 24 weeks
Study: 16448520
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg once daily for 24 weeks
Study: 12633795
Drug: Niacin ER/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER/lovastatin 1,000/40 mg
Study: 12633795
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and Simvastatin 20 mg
Study: 10835443
Drug: Ethanol in
Normalized name: ethanol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol in fruit juice (1.5 g/kg)
Study: 24380989
Drug: Erythromycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (125 mg in normal saline 50 cc)
Study: 22359078
Drug: Vitex agnus
Normalized name: VITEX AGNUS-CASTUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitex agnus castus (40 drops, administered for 6 days before menses for 6 consecutive cycles)
Study: 22359078
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo administered for 6 days before menses for 6 consecutive cycles)
Study: 17629361
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (23vPS)
Study: 15897479
Drug: Overall changes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall changes in insulin sensitivity (Si)
Study: 8545140
Drug: Strong opioid
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong opioid agonists
Study: 8545140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol and codeine
Study: 8545140
Drug: Treatment suggestions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment suggestions
Study: 1835005
Drug: Norethisterone, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone, 5 mg three times a day from day 19 to 26
Study: 1835005
Drug: Danazol, 200
Normalized name: Danazol, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 200 mg daily
Study: 7129917
Drug: Anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drugs and analgesics
Study: 9046253
Drug: Ahmed Glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed Glaucoma Valve implant
Study: 7639371
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0.2 mg/kg loading dose followed by 0.5 mg.kg-1.h-1 infusion
Study: 7639371
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0.4 mg/kg loading dose followed by 1 mg.kg-1.h-1 infusion
Study: 7639371
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0.5 mg/kg loading dose followed by 2 mg.kg-1.h-1 infusion
Study: 7639371
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0.7 mg/kg loading dose followed by 4 mg.kg-1.h-1 infusion
Study: 27726525
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with weekly face‐to‐face meetings to reduce BPA exposures, provided with BPA‐free cosmetics, hygiene products, glass containers, and self-monitoring tools
Study: 26185417
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg every other week (EOW)
Study: 26185417
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg EOW
Study: 23394779
Drug: GnRHant protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHant protocol (daily dose of recombinant FSH, cetrorelix, and rhCG microdose)
Study: 20192725
Drug: BID (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (400 mg lopinavir and 100 mg ritonavir twice daily)
Study: 20192725
Drug: QD (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD (800 mg lopinavir and 200 mg ritonavir once daily)
Study: 6342335
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily plus propantheline 45 mg daily (group A)
Study: 6342335
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily plus placebo (group B)
Study: 6342335
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at bedtime plus propantheline 45 mg daily
Study: 6342335
Drug: Propantheline 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline 90 mg daily
Study: 26462903
Drug: Humeral intraosseous
Normalized name: 1-36 human humoral hypercalcemic factor
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humeral intraosseous (HIO) epinephrine administration
Study: 26462903
Drug: Tibial intraosseous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibial intraosseous (TIO) epinephrine administration
Study: 26462903
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) epinephrine administration
Study: 18492754
Drug: Twice-daily PTH
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily PTH 1-34
Study: 18492754
Drug: Once-daily PTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily PTH 1-34
Study: 12823608
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and melatonin (20 mg/day orally in the evening)
Study: 12823608
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and melatonin
Study: 10672721
Drug: Perfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion of the kidney cavitary system with the drug Palisan
Study: 8729614
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (CHOP or CHOP-like)
Study: 6616485
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (local chemotherapy with Adriamycin)
Study: 29332428
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus preoperative preparation (tour, cartoon video, familiarization with medical equipment)
Study: 22496199
Drug: Paroxetine (SSRI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (SSRI), 40 mg maximum daily dosage
Study: 22496199
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (SNRI), 225 mg maximum daily dosage
Study: 20920046
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of insulin secretagogues
Study: 20920046
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of insulin secretagogues (Control)
Study: 17656354
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine (0.1%) containing fentanyl (2 microg ml(‐1))
Study: 11403537
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of H(2)-receptor antagonists
Study: 11403537
Drug: Misoprostol (low-dose)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (low-dose)
Study: 3059850
Drug: Open challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open challenge with a large dose (3 g/kg) of candy bar sucrose
Study: 27017207
Drug: TAP-144-SR (6M)
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (6M) 22.5 mg
Study: 27017207
Drug: TAP-144-SR (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (3M) 11.25 mg
Study: 27190347
Drug: High-clearance period
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-clearance period (PCS: 23 ± 4 mL/min; IS: 30 ± 5 mL/min)
Study: 27190347
Drug: Low-clearance period
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-clearance period (PCS: 12 ± 3 mL/min; IS: 17 ± 4 mL/min)
Study: 24375969
Drug: Text messaging-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging-assisted lifestyle weight loss intervention (3 group sessions, 5 coaching calls, daily text messages)
Study: 17341532
Drug: CoQ10 50
Normalized name: Nature Made CoQ10 50mg Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 50 mg
Study: 15105190
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid treatment plus moderate acute normovolemic hemodilution (ANH)
Study: 15105190
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid treatment (control group)
Study: 9255857
Drug: Telephone-administered mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered mood ratings (SIGH-SAD)
Study: 9255857
Drug: Telephone-administered mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered mood ratings (HIGH-SAD)
Study: 8101467
Drug: Levocabastine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (twice daily)
Study: 8101467
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (four times daily)
Study: 3098484
Drug: Intravenous PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGE1 infusion